Treatment preferences of originator versus biosimilar drugs in Crohns disease; Discrete choice experiment among gastroenterologists

Petra Baji, L. Gulácsi, Barbara D. Lovász, Petra A. Golovics, Valentin Brodszky, Márta Péntek, Fanni Rencz, P. Lakatos

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective. To explore preferences of gastroenterologists for biosimilar drugs in Crohns disease. Material and methods. Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-naïve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. Results. Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% versus 11% for new patients, and 44% versus 56% for patients already treated with biological. Conclusions. For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.

Original languageEnglish
Pages (from-to)22-27
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume51
Issue number1
DOIs
Publication statusPublished - Jan 2 2016

Fingerprint

Biosimilar Pharmaceuticals
Crohn Disease
Pharmaceutical Preparations
Therapeutics
Logistic Models
Medicine
Gastroenterologists
Consultants
Inflammatory Bowel Diseases

Keywords

  • Biologicals
  • biosimilars
  • Crohn's disease
  • discrete choice experiment
  • preference

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment preferences of originator versus biosimilar drugs in Crohns disease; Discrete choice experiment among gastroenterologists. / Baji, Petra; Gulácsi, L.; Lovász, Barbara D.; Golovics, Petra A.; Brodszky, Valentin; Péntek, Márta; Rencz, Fanni; Lakatos, P.

In: Scandinavian Journal of Gastroenterology, Vol. 51, No. 1, 02.01.2016, p. 22-27.

Research output: Contribution to journalArticle

Baji, Petra ; Gulácsi, L. ; Lovász, Barbara D. ; Golovics, Petra A. ; Brodszky, Valentin ; Péntek, Márta ; Rencz, Fanni ; Lakatos, P. / Treatment preferences of originator versus biosimilar drugs in Crohns disease; Discrete choice experiment among gastroenterologists. In: Scandinavian Journal of Gastroenterology. 2016 ; Vol. 51, No. 1. pp. 22-27.
@article{59516d84b01c4ecd88a8e09ecf05f10a,
title = "Treatment preferences of originator versus biosimilar drugs in Crohns disease; Discrete choice experiment among gastroenterologists",
abstract = "Objective. To explore preferences of gastroenterologists for biosimilar drugs in Crohns disease. Material and methods. Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-na{\"i}ve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. Results. Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-na{\"i}ve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-na{\"i}ve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89{\%} versus 11{\%} for new patients, and 44{\%} versus 56{\%} for patients already treated with biological. Conclusions. For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.",
keywords = "Biologicals, biosimilars, Crohn's disease, discrete choice experiment, preference",
author = "Petra Baji and L. Gul{\'a}csi and Lov{\'a}sz, {Barbara D.} and Golovics, {Petra A.} and Valentin Brodszky and M{\'a}rta P{\'e}ntek and Fanni Rencz and P. Lakatos",
year = "2016",
month = "1",
day = "2",
doi = "10.3109/00365521.2015.1054422",
language = "English",
volume = "51",
pages = "22--27",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Treatment preferences of originator versus biosimilar drugs in Crohns disease; Discrete choice experiment among gastroenterologists

AU - Baji, Petra

AU - Gulácsi, L.

AU - Lovász, Barbara D.

AU - Golovics, Petra A.

AU - Brodszky, Valentin

AU - Péntek, Márta

AU - Rencz, Fanni

AU - Lakatos, P.

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Objective. To explore preferences of gastroenterologists for biosimilar drugs in Crohns disease. Material and methods. Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-naïve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. Results. Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% versus 11% for new patients, and 44% versus 56% for patients already treated with biological. Conclusions. For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.

AB - Objective. To explore preferences of gastroenterologists for biosimilar drugs in Crohns disease. Material and methods. Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-naïve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. Results. Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% versus 11% for new patients, and 44% versus 56% for patients already treated with biological. Conclusions. For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.

KW - Biologicals

KW - biosimilars

KW - Crohn's disease

KW - discrete choice experiment

KW - preference

UR - http://www.scopus.com/inward/record.url?scp=84944931026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944931026&partnerID=8YFLogxK

U2 - 10.3109/00365521.2015.1054422

DO - 10.3109/00365521.2015.1054422

M3 - Article

VL - 51

SP - 22

EP - 27

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 1

ER -